1. Interleukin‐38 alleviates cardiac remodelling after myocardial infarction
- Author
-
Qiutang Zeng, Yuzhen Wei, Kunwu Yu, Yin Lan, Ruirui Zhu, Yan Ding, Yue Wang, Yucheng Zhong, Wenbin Xu, and Haitao Sun
- Subjects
Male ,0301 basic medicine ,Cardiac function curve ,medicine.medical_specialty ,medicine.medical_treatment ,Myocardial Infarction ,Apoptosis ,Inflammation ,T-Lymphocytes, Regulatory ,03 medical and health sciences ,0302 clinical medicine ,interleukin‐38 ,Internal medicine ,Troponin I ,Immune Tolerance ,medicine ,Animals ,Myocytes, Cardiac ,RNA, Messenger ,Myocardial infarction ,Ventricular Remodeling ,business.industry ,cardiac remodelling ,Interleukin ,Dendritic Cells ,Original Articles ,Cell Biology ,Acquired immune system ,medicine.disease ,Fibrosis ,Survival Analysis ,Mice, Inbred C57BL ,Phenotype ,030104 developmental biology ,Cytokine ,030220 oncology & carcinogenesis ,Cardiology ,Molecular Medicine ,Original Article ,Myocardial fibrosis ,medicine.symptom ,business ,Interleukin-1 - Abstract
Excessive immune‐mediated inflammatory reaction plays a deleterious role in ventricular remodelling after myocardial infarction (MI). Interleukin (IL)‐38 is a newly characterized cytokine of the IL‐1 family and has been reported to exert a protective effect in some autoimmune diseases. However, its role in cardiac remodelling post‐MI remains unknown. In this study, we found that the expression of IL‐38 was increased in infarcted heart after MI induced in C57BL/6 mice by permanent ligation of the left anterior descending artery. In addition, our data showed that ventricular remodelling after MI was significantly ameliorated after recombinant IL‐38 injection in mice. This amelioration was demonstrated by better cardiac function, restricted inflammatory response, attenuated myocardial injury and decreased myocardial fibrosis. Our results in vitro revealed that IL‐38 affects the phenotype of dendritic cells (DCs) and IL‐38 plus troponin I (TNI)‐treated tolerogenic DCs dampened adaptive immune response when co‐cultured with CD4+T cells. In conclusion, IL‐38 plays a protective effect in ventricular remodelling post‐MI, one possibility by influencing DCs to attenuate inflammatory response. Therefore, targeting IL‐38 may hold a new therapeutic potential in treating MI.
- Published
- 2019